According to research by SNS Insider, the U.S. Viral Vector Manufacturing Market is projected to grow at a CAGR of 21.26%, driven by rapid expansion in gene therapy development, rising outsourcing to contract manufacturers, and strong momentum in clinical trial deployments.
Austin, Nov. 24, 2025 (GLOBE NEWSWIRE) — Viral Vector Manufacturing Market Size & Growth Analysis:
According to a comprehensive report by SNS Insider, the Viral Vector Manufacturing Market size is estimated at USD 2.23 billion in 2025 and is projected to reach USD 10.65 billion by 2033. This reflects a powerful compound annual growth rate (CAGR) of 21.65% during 2026 to 2033. The global biotechnology landscape is undergoing rapid transformation as cell and gene therapies gain approval and advance across clinical phases. Viral vectors remain the backbone of these therapies, enabling precise and efficient delivery of genetic material to treat cancer, rare diseases, and inherited disorders.
Get Free Sample Report of the Viral Vector Manufacturing Market: https://www.snsinsider.com/sample-request/8781
The United States continues to hold a leading position in viral vector production. The U.S. Viral Vector Manufacturing Market size is estimated at USD 0.73 billion in 2025 and is expected to reach USD 3.38 billion by 2033 at a CAGR of 21.26%. Growth is fueled by strong federal support for advanced therapies, an increasing number of gene therapy trials, expansion of biomanufacturing capabilities, and strategic partnerships among biotech innovators and contract development and manufacturing organizations (CDMOs).
Major Companies in the Viral Vector Manufacturing Market Include:
- Lonza
- Thermo Fisher Scientific
- Charles River Laboratories
- Fujifilm Diosynth Biotechnologies
- Catalent
- Kaneka Eurogentec
- Merck KGaA (MilliporeSigma)
- Oxford Biomedica
- uniQure NV
- Spark Therapeutics (Roche)
- Cytiva (Danaher)
- Yposkesi (Servier)
- Viralgen Vector Core
- Aldevron
- Vibalogics
- Waisman Biomanufacturing
- Novasep
- Genezen
- bluebird Bio
- REGENXBIO
Segmentation Analysis:
By Diseases
The cancer segment led the market with a 48.25% share in 2025 owing to a high occurrence of different types of cancer and an increasing requirement for innovative gene therapies developed for treating oncologic diseases. Genetic disorders were the fastest-growing segment, registering a CAGR of 18.14%. Increasing awareness, government programs, and increasing diagnostic rates also drive adoption in this segment.
By Application
The gene therapy segment dominated the market with a 55.31% share in 2025 due to a widespread use in clinics, increasing availability of approved therapies and growing demand from patients for personalized treatment. Vaccinology was the fastest-growing segment, with a CAGR of 16.53% owing to the development of new viral vector-based vaccines for infectious diseases increasing production demands.
By Type
Adeno-associated viral vectors led the market with 34.23% in 2025 due to the most prevalent vectors for several reasons, including their lack of pathogenicity, sustained gene expression and demonstrated efficacy in a wide variety of therapeutic indications. Lentiviral vectors registered the fastest growth at a CAGR of 15.47% driven by progress in ex-vivo therapies, CAR-T treatments, and new dimensions in regenerative medicine.
By Mofe of Manufacturing
The in-house manufacturing held 51.68% of the market in 2025 as big biotech and pharma prefer to keep quality control and accountability within. CDMOs were the fastest-growing segment, recording a CAGR of 17.44% due to propelled by trends such as more outsourcing, capacity limitations, and demand for scalable cost-effective commercial production.
Need Any Customization Research on Viral Vector Manufacturing Market, Enquire Now: https://www.snsinsider.com/enquiry/8781
Regional Insights:
In 2025, North America dominated the Viral Vector Manufacturing Market and accounted for 45.31% of revenue share, due to the developed infrastructure, supportive regulator environment, and high penetration of gene therapies.
Asia Pacific is expected to witness the fastest growth in the Viral Vector Manufacturing Market over 2026-2033, with a projected CAGR of 22.39% due to the rapid adoption of gene therapeutics and increasing clinical trial activity. Australia, Japan and South Korea are building new manufacturing capacity to satisfy local and global demand. Investing in new Viral Vector technologies and favorable government initiatives to boost market growth.
Recent Developments:
- In October 2025, Lonza introduced new GMP-grade cytokine and media systems designed to enhance scalability, consistency, and efficiency in viral vector and cell therapy production. This advancement aims to support the growing demand for gene therapies and improve manufacturing processes.
- In September 2025, Thermo Fisher Scientific partnered with Dr. Park CDMO to equip a new viral vector manufacturing facility. This collaboration reflects the increasing importance of robust viral vector manufacturing as cell and gene therapies move from research to clinical and commercial use.
Exclusive Sections of the Report (The USPs):
- CAPACITY UTILIZATION & PRODUCTION PERFORMANCE METRICS – helps you assess operational efficiency across CMOs and in-house facilities through capacity use, annual output levels, and manufacturing lead-time indicators.
- INVESTMENT & FUNDING MOMENTUM INDEX – helps you evaluate the flow of venture capital, private equity, M&A activity, and R&D spending trends that shape market expansion and technology development.
- REGULATORY & CLINICAL APPROVAL LANDSCAPE – helps you understand approval trends across FDA, EMA, and PMDA, alongside clinical trial adoption rates of various viral vectors and average approval timelines.
- SUPPLY CHAIN & MANUFACTURING FOOTPRINT ANALYTICS – helps you map global facility distribution, analyze outsourcing vs. in-house production mix, and identify bottlenecks impacting supply continuity.
- TECHNOLOGY & TRIAL UTILIZATION INSIGHTS – helps you uncover which viral vector types dominate gene therapy trials, enabling better prioritization for R&D and commercialization strategies.
Buy the Full Viral Vector Manufacturing Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/8781
Viral Vector Manufacturing Market Report Scope
| Report Attributes | Details |
| Market Size in 2025E | USD 2.23 Billion |
| Market Size by 2033 | USD 10.65 Billion |
| CAGR | CAGR of 21.65% From 2026 to 2033 |
| Base Year | 2025E |
| Forecast Period | 2026-2033 |
| Historical Data | 2022-2024 |
| Key Segments | • By Diseases (Cancer, Genetic Disorders, Infectious Diseases, and Others)
• By Application (Gene Therapy and Vaccinology) • By Type (Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others) • By Mode of Manufacturing (In-House Manufacturing and CDMOs) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Access Complete Report Details of Viral Vector Manufacturing Market Analysis and Outlook: https://www.snsinsider.com/reports/viral-vector-manufacturing-market-8781
[For more information or to request custom research, email us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.
